CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells

International Immunopharmacology

Volumn 6, Issue 13-14, 2006, Pages 2057-2068

  Ponzio, Nicholas M ^a,c   Cutro, Scott ^a   Hu, Jessica ^a   Marzouk, Atara ^a   Marshall, Jason D ^b  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b Dynavax Technologies Corporation   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Cytotoxic T lymphocyte; Innate immune system; Interleukin 12; Reverse Immune Surveillance; T helper 1 cell; Tumor immunity

Indexed keywords

B7 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; ISS 1018; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; CANCER GROWTH; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; GERMINAL CENTER; IMMUNITY; IN VITRO STUDY; INCUBATION TIME; LYMPH NODE; LYMPHOMA CELL; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SURVIVAL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; B-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GERMINAL CENTER; HISTOCOMPATIBILITY ANTIGENS; IMMUNOLOGIC FACTORS; INTERLEUKIN-12; LYMPH NODES; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED STRAINS; OLIGODEOXYRIBONUCLEOTIDES; SPLEEN; SURVIVAL ANALYSIS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 33845322650     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.08.008     Document Type: Article

References (58)

1. Murphy E.D. SJL/J, a new inbred strain of mouse with a high, early incidence of reticulum-cell neoplasms. Proc Am Assoc Cancer Res 4 (1963) 46
2. Ponzio N.M., Lerman S.P., Chapman J., and Thorbecke G.J. Properties of reticulum cell sarcomas in SJL/J mice IV. Minimal development of cytotoxic cells despite marked proliferation to syngeneic RCS in vivo and in vitro. Cell Immunol 32 (1977) 10-22
3. Ponzio N.M., Chapman-Alexander J., and Thorbecke G.J. Properties of reticulum cell sarcomas in SJL/J mice VI. Characterization of lymphoid cells that proliferate in response to RCS cells. Cell Immunol 41 (1978) 157-171
4. Ponzio N.M., Fitzgerald K., Vilcek J., and Thorbecke G.J. Spontaneous production of T (Type II) interferon by a murine reticulum-cell sarcoma. Ann N Y Acad of Sci 350 (1980) 157-167
5. + T cells. J Immunol 150 (1993) 5519-5528
6. Tsiagbe V.K., Yoshimoto T., Asakawa J., Cho S., Meruelo D., and Thorbecke G.J. Linkage of superantigen-like stimulation of syngeneic T cells in a mouse model of follicular center B cell lymphoma to transcription of endogenous mammary tumor virus. EMBO J 12 (1993) 2313-2320
7. Tsiagbe V.K., Asakawa J., Yoshimoto T., Cho S., Meruelo D., and Thorbecke G.J. MTV-encoded superantigen expression in B lymphoma cells in SJL mice as a stimulus for "reversed immunological surveillance". Superantigens: A pathogen's view of the immune system (1993), Cold Spring Harbor Laboratory Press 93-115
8. Ponzio N.M., Zhang D.-J., Tsiagbe V.K., and Thorbecke G.J. Influence of MTV superantigen on B cell lymphoma in SJL/J mice. In: Tomonari K. (Ed). Viral superantigens (1997), CRC Press Inc., Boca Raton, FL 219-231
9. Wajchman J., Simmons W., Klein A., Koneru M., and Ponzio N.M. Interleukin-12-induced cytotoxicity against syngeneic B cell lymphomas of SJL/J mice. Leuk Res 26 (2002) 577-590
10. Simmons W.J., Koneru M., Mohindru M., Thomas R., Cutro S., Singh P., et al. Tim-3+ T-bet+ tumor specific TH1 cells co-localize with and inhibit development and growth of murine neoplasms. J Immunol 174 (2005) 1405-1415
11. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20 (2002) 709-760
12. Yu D., Kandimalla E., Ghagat L., Tang J., Cong Y., Tang J., et al. 'Immunomers'-novel 3′-3′-linked CpG oligodeoxyribonucleotides as potent immunomodulatory agents. Nucleic Acids Res 30 (2002) 4460-4469
13. Lenert P., Goeken A., and Ashman R. Extended sequence preferences for oligodeoxyribonucleotide activity. Immunology 117 (2006) 474-481
14. Bauer M., Heeg K., Wagner H., and Lipford G. DNA activates human immune cells through a CpG sequence-dependent manner. Immunology 97 (1999) 699-705
15. Tascon R., Ragno S., Lowrie D., and Colston M. Immunostimulatory bacterial DNA sequences activate dendritic cells and promote priming nad differentiation of CD8+ T cells. Immunology 99 (2000) 1-7
16. Krug A., Towarowski A., Britsch S., Rothenfusser S., Hornung V., Bals R., et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 31 (2001) 3026-3037
17. Maurer T., Heit A., Hochrein H., Ampenberger F., O'Keeffe M., Bauer S., et al. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur J Immunol 32 (2002) 2356-2364
18. Maletto B., Ropolo A., Moron V., and Pistoresi-Palencia M. CpG-DNA stimulates cellular and humoral immunity and promotes TH1 differentiation in aged BALB/ mice. J Leukoc Biol 72 (2002) 447-454
19. Zwaveling S., Ferreira Mota S., Nouta J., Johnson M., Lipford G., Offringa R., et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 169 (2002) 350-358
20. Baines J., and Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res 9 (2003) 2693-2700
21. Weigel B., Rodeberg D., Krieg A., and Blazar B.R. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 9 (2003) 105-1014
22. Kawarada Y., Ganss R., Garbi N., Sacher T., Arnold B., and Hammerling G. NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J Immunol 167 (2004) 5247-5253
23. Hafner M., Zawatzky R., Hirtreiter C., Buurman W., Echtenacher B., Hehlgans T., et al. Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Res 61 (2001) 5523-5528
24. Carpentier A., Xie J., Mokhtari K., and Delattre J. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res 6 (2002) 2469-2473
25. Krieg A. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta 1489 (1999) 107-116
26. Bauer M., Redecke V., Ellwart J., Scherer B., Kremer J., Wagner H., et al. Bacterial CpG-DNA triggers activation and maturation of human CD11c(-), CD123(+) dendritic cells. J Immunol 166 (2001) 5000-5007
27. Gursel M., Verthelyi D., Gursel I., Ishii K., and Klinman D. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol 71 (2002) 813-820
28. Magone M., Chan C., Beck L., Whitcup S., and Raz E. Systemic or mucosal administration of immunostimulatory DNA inhibits early and late phases of murine allergic conjunctivitis. Eur J Immunol 30 (2000) 1841-1850
29. Broide D., Stachnick G., and Castaneda D. Systemic administration of immunostimulatory DNA sequences mediates reversible inhibition of Th2 responses in a mouse model of asthma. J Clin Immunol 21 (2001) 175-182
30. Herbst M., and Pyles R. Immunostimulatory CpG treatment for genital HSV-2 infections. J Antimicrob Chemother 52 (2003) 887-889
31. Teleshova N., Kenney J., and Jones J. CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells. J Immunol 173 (2004) 1647-1657
32. Friedberg J., Kim H., McCauley M., Hessel E., Sims P., Fisher D., et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 105 (2005) 489-495
33. Tsiagbe V.K., Ponzio N.M., Erianne G.S., Zhang D.J., Thorbecke G.J., and Inghirami G. Germinal center derived lymphomas in humans and mice (1998), Landes Bioscience, Georgetown, TX
34. Ponzio N.M., Tsiagbe V.K., and Thorbecke G.J. Superantigens related to B cell hyperplasia. Springer Semin Immunopathol 17 (1996) 285-306
35. Marshall J., Fearon K., Abbate C., Subramanian S., Yee P., Gregorio J., et al. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. J Leukoc Biol 73 (2003) 781-792
36. Alisauskas R.M., and Ponzio N.M. T-helper-cell-specific monoclonal antibody inhibits growth of B-cell lymphomas in syngeneic SJL/J mice. Cell Immunol 119 (1989) 286-303
37. Simmons W.J., Simms M., Chiarle R., Mackay F., Tsiagbe V.K., Browning J., et al. Induction of germinal centers by MMTV encoded superantigen on B cells. Dev Immunol 8 (2001) 201-211
38. Beisel K.W., and Lerman S.P. Progressive loss of H-2Ds antigens during passage of a spontaneous SJL/J lymphoma. Transplant Proc XIII (1981) 1811-1813
39. + B cell lymphoma arising in a CD4 monoclonal antibody-treated SJL mouse. Clin Immunol Immunopathol 65 (1992) 10-22
40. Erianne G.J., Wajchman J., and Ponzio N.M. B lymphoma cells of C57L mice; the role of Natural Killer cells and T helper cells in lymphoma development and growth. Leuk Res 24 (2000) 705-718
41. Herberman R., Nunn M., and Holden H. Low density of Thy-1 antigen on mouse effector cells mediating natural cytotoxicity against tumor cells. J Immunol 121 (1978) 988
42. Krug A., Rothenfusser S., Hornung V., Jahrsdorfer B., Blackwell S., Ballas Z.K.., et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 31 (2001) 2154-2163
43. Thorbecke G.J., and Ponzio N.M. Reverse immune surveillance: an adaptive mechanism used by tumor cells to facilitate their survival and growth. Semin Cancer Biol 10 (2000) 327-330
44. Murphy E.D. Transplantation behavior of Hodgkin's-like reticulum cell neoplasms of the strain SJL/J mice and results of tumor reinoculation. J Natl Cancer Inst 42 (1969) 797-814
45. Carswell E., Wanebo H., Old L., and Boyse E. Immunologic properties of reticulum cell sarcomas of SJL/J mice. J Natl Cancer Inst 44 (1970) 1281-1288
46. Jahrsdorfer B., Hartmann G., Racila E., Jackson W., Muhlenhoff L., Meinhardt G., et al. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 69 (2001) 81-88
47. Krieg A., Yi A., Matson S., Waldschmidt T., Bishop G., Teasdale R., et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 (1995) 546-549
48. Marshall J.D., Heeke D.S., Abbate C., Yee P., and Van Nest G. Induction of interferon-gamma from natural killer cells by immunostimulatory CpG DNA is mediated through plasmacytoid-dendritic-cell-produced interferon-alpha and tumour necrosis factor-alpha. Immunol 117 (2006) 38-46
49. Marshall J.D., Higgins D., Abbate C., Yee P., Teshima G., Ott G., et al. Polymyxin B enhances ISS-mediated immune responses across multiple species. Cell Immunol 229 (2004) 93-105
50. Jahrsdorfer B., and Weiner G. CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy. Curr Opin Investig Drugs (2003) 686-690
51. Jahrsdorfer B., Muhlenhoff L., Blackwell S., Wagner M., Poeck H., Hartmann E., et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res 11 (2005) 1490
52. Decker T., and Peschel C. Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells. Leuk Lymphoma 42 (2001) 301-307
53. Wooldridge J., Ballas Z., Krieg A., and Weiner G. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 89 (1997) 2994-2998
54. Warren T., Dahle C., and Weiner G. CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clin Lymphoma 1 (2000) 57-61
55. Chen W., Yu Y., Shao C., Zhang M., Wang W., Zhang L., et al. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody. Immunol Lett 77 (2001) 17-23
56. Jahrsdorfer B., Wooldridge J., Blackwell S., Taylor C., Griffith T., Link B., et al. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J. Leukoc Biol 77 (2005) 378-387
57. Levy R. Study of intratumoral injection of CpG 7909, a TLR 9 agonist, combined with local radiation in recurrent low-grade lymphomas (2004). NCT00185965
58. Freedman A., and Ronan E. Study of Dynavax's 1018 ISS, following Rituxan in patients with B-cell follicular lymphoma (2004). NCT00251394